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PHARMACOECONOMIC ANALYSIS OF ERLOTINIB COMPARED
WITH DOCETAXEL FORTHETREATMENT OF RELAPSED
NON-SMALL-CELL LUNG CANCER (NSCLC) INTURKEY
Batigun O,Yildirim E
Roche Müstahzarlari Sanayi AS, Istanbul, Maslak-Istanbul,Turkey
OBJECTIVES: To perform a cost-utility analysis of erlotinib
compared with docetaxel for treatment of advanced NSCLC
following the failure of prior chemotherapy from the perspective
of the Turkey health care system. METHODS: A cost-utility
analysis was performed using a transition model with three
health states (progression free, progression, death); primary end-
point of cost per quality-adjusted life year (QALY) gained. The
model compared the impact of erlotinib or docetaxel therapy
over a 2-year period (cycle length of 1 month) in patients with
stage IIIB/IV NSCLC who had failed at least one prior chemo-
therapy regimen. Clinical data from the BR.21 (erlotinib) and
TAX317 (docetaxel) phase III studies were used; for the purposes
of this analysis, it was conservatively assumed that overall sur-
vival was equivalent for the two interventions. The time spent in
each health state was adjusted for quality of life, including the
impact of adverse events (AEs). Costs included were: resource
utilisation for each health state and AE (including hospitalisa-
tion, physician visits, outpatient examinations, concomitant
medicines and required tests), drug acquisition and administra-
tion. RESULTS: The total discounted cost of erlotinib was
21,498 YTL (€11,943), compared with 21,667 YTL (€12,037)
for docetaxel. Erlotinib was associated with higher QALYs than
docetaxel (0.258 versus 0.206; incremental QALYs = 0.053),
mainly due to the lower incidence of AEs and the administra-
tion route (oral, versus intravenous for docetaxel). Erlotinib
was dominant versus docetaxel, with an incremental cost-
effectiveness ratio of –3227 YTL (–€1792) per QALY gained.
CONCLUSION: This is the ﬁrst pharmacoeconomic modelling
analysis performed for the setting of the Turkish health care
system. The results show that erlotinib is dominant versus doc-
etaxel for the treatment of relapsed advanced NSCLC, providing
higher QALYs at a lower cost. A major contributing factor to the
cost-savings observed with erlotinib is its favourable AE proﬁle,
particularly its lack of haematological toxicity.
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HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION
AFTER BREAST CONSERVING SURGERY IN LOW-INCOME
MEDICAID-ENROLLED WOMEN
Anderson RT1, Balkrishnan R2
1Wake Forest University School of Medicine,Winston Salem, NC,
USA, 2The Ohio State University College of Pharmacy, Columbus,
OH, USA
OBJECTIVES: Breast-conserving surgery (BCS), followed by
radiation therapy (RT) is a safe and effective alternative to mas-
tectomy for most women with early stage breast cancer based on
evidence from prospective randomized trials, and has become the
preferred surgical option. Omission of RT after BCS, however, is
increasingly common and leads to poor outcomes. Few studies
examine patient and health system correlates to receipt of RT
after BCS, especially in a low income population. This study
described patient and health care systems correlates of receipt of
recommended care with BCS in North Carolina (NC) indicated
by receipt of adjuvant RT. METHODS: Subjects were women
diagnosed with primary breast cancer in 1998 and 1999 who
were classiﬁed as alive at least 12 months post-treatment with
BCS (N = 344). Medicaid claims were obtained to supplement
central cancer registry data on adjuvant RT; state county data
were obtained on health provider shortage regions. RESULTS:
Of 344 women in NC enrolled in Medicaid and treated with BCS
during the period of study, one third did not receive RT. The
following factors were associated with lack of receipt of RT after
BCS older age (65 > years), residence in a low population density
county, receiving BCS at a smaller-sized hospital, and living in a
county classiﬁed as whole-county specialist scarcity area (all
p < 0.05 in multivariate analyses). CONCLUSION: Some low
income women do not access RT following BCS, placing them at
risk for recurrence. We identiﬁed geographic isolation and scar-
city of health care as possible leverage points for interventions.
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ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE
USE,AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN
FIVE EUROPEAN COUNTRIES
Leeuwenkamp O1, Knapp M2, McCrone P3
1NV Organon, Molenstraat, Oss,The Netherlands, 2London School of
Economics, London, UK, 3King’s College London, London, UK
OBJECTIVES: To allocate mental health resources effectively,
data are needed on resource use and costs associated with schizo-
phrenia. We analyzed the use and costs of clinical services in
patients with vs without negative symptoms of schizophrenia.
METHODS: Data were drawn from the cross-sectional Euro-
pean Psychiatric Services: Inputs Linked to Outcome Domains
and Needs (EPSILON) study, which was conducted in Amster-
dam, The Netherlands; Copenhagen, Denmark; London,
England; Santander, Spain; and Verona, Italy. Using Brief Psychi-
atric Rating Scale (BPRS) data, we produced three alternative
measures of negative symptoms: 1) a binary variable indicating
presence or absence of negative symptoms; 2) mean score for
individual BPRS negative symptom items; and 3) principal com-
ponents analysis of BPRS negative symptom items. We used
multiple regression models to analyze the impact of negative
symptoms on the use and costs of inpatient, outpatient, and
community-based services, controlling for age, sex, marital
status, employment status, race, education, psychiatric history,
and study center. RESULTS: Negative symptoms were present in
247 of 404 patients, with the lowest prevalence in Verona (49%)
and the highest in Amsterdam (79%). Compared with patients
with no negative symptoms, patients with negative symptoms
incurred higher mean costs for inpatient care (68% higher), day
care (116% higher), community services (48% higher), residen-
tial care (180% higher), and total costs (68% higher) but lower
costs for outpatient care (42% lower). After adjusting for socio-
demographic and clinical variables, negative symptoms were still
signiﬁcantly associated with higher inpatient and total costs. In
the analysis of service use, a signiﬁcant inverse relationship was
seen between the negative symptoms component score and use of
outpatient services. CONCLUSION: In this study of patients
with schizophrenia in ﬁve European countries, negative symp-
toms were most consistently correlated with higher inpatient and
total costs. Further investigation is merited.
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ASSESSINGTHE IMPACT OF A NATIONAL DRUG BENEFIT
PROGRAM ONTHE USE OF GENERIC DRUGS AND
DIFFERENTTHERAPEUTIC CLASSES
Zhang JX1,Yin W1, Sun SX2, Lee KY2, Meltzer DO1,Alexander GC1
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services,
Deerﬁeld, IL, USA
OBJECTIVES: To examine changes in the utilization of prescrip-
tion medicines from 16 therapeutic classes from 2005 to 2006
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attributable to the institution of Medicare Part D, a national
prescription drug beneﬁt program for the elderly instituted at the
end of 2005 in the United States. METHODS: We implemented
retrospective analyses of pharmacy claims of beneﬁciaries aged
67–79 years from 2005 to 2006, from a large pharmacy chain in
the United States. Subjects aged 61–63 were used a control group
in a differences-in-differences approach to account for trends not
related to Part D. The ﬁnal sample represented approximately
2.4 million unique beneﬁciaries aged 67–79. The main outcomes
are: 1) Changes in proportion of total days of therapy dispensed
as generics, and 2) changes in prescription utilization for each
therapeutic class. RESULTS: Prescription drug use by these ben-
eﬁciaries increased by 11% from 2005 to 2006. After adjustment
for secular trends and other potential confounders, utilization of
each therapeutic class was similar in 2005 and 2006. Small
increases in drug utilization occurred for several drug classes,
ranging from 0.66 pill days (0.46%) for users of nonsteroidal
anti-inﬂammatories (NSAIDs) to 4.64 pill days (1.78%) for users
of angiotensin-converting enzyme (ACE) inhibitors. Decreases
occurred for anti-diabetic drugs (–2.06 pill days, –0.58%), beta-
blockers (–1.24, –0.49%), and benzodiazepines (–5.96 pill days,
–3.57%). Overall, beneﬁciaries were slightly less likely to ﬁll
prescriptions for generic drugs vs. brand-name drugs in 2006
compared to 2005 (OR 0.98, 95% CI 0.97–0.98). CONCLU-
SION: Small increases in prescription drug utilization occurred
across numerous drug classes for these Medicare seniors follow-
ing the implementation of the Medicare Part D Prescription
Beneﬁt, while overall market share by drug class did not change
signiﬁcantly. Further analyses are needed to explore the degree to
which these changes reﬂect moral hazard versus beneﬁcial expan-
sions of coverage.
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PROMOTING A DRUG’S HEALTH ECONOMIC ADVANTAGES IN
MEDICAL JOURNAL ADVERTISING INTHE U.S.:A REVIEW OF
3,500 ADS FROM 1990–2006
Neumann PJ, Palmer JA,Timm AR
Tufts-New England Medical Center, Boston, MA, USA
OBJECTIVES: To quantify and characterize economic-content
in pharmaceutical advertisements, and its supporting evidence,
in leading American medical journals from 1990–2006.
METHODS: Two researchers reviewed all pharmaceutical adver-
tisements in three leading general medical (New England Journal
of Medicine, JAMA, and Annals of Internal Medicine) and spe-
cialty journals (Circulation, Gastroenterology, Neurology) in
three speciﬁed months each year for 2000 through 2006. Using a
standardized data collection form, we investigated economic
claims (e.g., ads using the words “value”, “price”, “savings”,
“hospitalization,” etc.), as well as the supporting evidence. This
work builds upon our previous research of economic claims from
1990–1999, adding new data and content. RESULTS: We
reviewed 3,516 pharmaceutical advertisements (2,144 from
1990–1999 and 1372 from 2000–2006). Economic content
occurred in 11.1% of ads in the 1990s, and 7.6% of ads in
2000–2006 (p = 0.0007). From 1997 to 2002, economic adver-
tisements declined (p < 0.0001), and increased again from 2003–
2006 (p = 0.0006), with a peak in 1997 at 16.2% and a nadir of
3.9% in 2002. Economic claims appeared with similar frequency
in the specialty journal ads across time periods (1990s: 8.6% vs.
2000–2006: 8.5%; p = 0.91), but declined in the general medical
journal ads (1990s: 13.0% vs. 2000–2006: 6.4%; p < 0.0001).
The presence of supporting evidence for economic claims was
similar in the 1990s and 2000s (63.7% vs. 61.5%, p = 0.70), but
over time derived less from the Red Book (1990s: 38.7% vs.
2000–2006: 15.6%) and average wholesale price listings (1990s:
51.1% vs. 2000–2006: 6.3%) and more from data on ﬁle (1990s:
9.5% vs. 2000–2006: 29.7%) and published studies (1990s:
6.6% vs. 2000–2006: 23.4%). From 2000–06, a small number of
ads mentioned patient compliance (2.6%) or persistence (2.0%).
CONCLUSION: Drug companies continue to promote health
economic messages in medical journal advertisements. Mention
of supporting evidence underlying economic claims has not
changed over time, though more ads reference published studies.
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IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH
CARE RESOURCE UTILIZATION IN PATIENTS WITH
IMMUNE-MEDIATED INFLAMMATORY DISEASES
Tang B1, Rahman MI1, Stephenson JJ2, Quimbo RA2,Thompson HC1,
Naim A1, Dabbous O1
1Centocor, Inc, Horsham, PA, USA, 2HealthCore Inc,Wilmington, DE,
USA
OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (anti-TNF) therapy on real world health care resource
utilization in patients with immune-mediated inﬂammatory dis-
eases (IMIDs). METHODS: Three groups of patients were iden-
tiﬁed using claims data from Blue Cross Blue Shield health plans:
IMID (rheumatoid arthritis, ankylosing spondylitis, Crohn’s
disease, psoriatic arthritis, psoriasis or ulcerative colitis) patients
receiving anti-TNF therapy between January 1, 2003 and June
30, 2005 (Group 1); IMID controls without anti-TNF therapy
(Group 2); and non-IMID controls (Group 3). The groups were
matched for gender, age and geographic region in a 3:1 ratio. All
patients had > = 6 months continuous plan enrollment before
and > = 12 months after the index date. Health care resource
utilizations per patient per month (PPPM) were calculated for the
6-month pre- and 12-month post-index periods. Differences from
baseline were compared among three groups. RESULTS: After
matching, 27,006 patients (3,970 Group 1; 11,718 Group 2; and
11,318 Group 3) were analyzed. Of these, 61% were female and
the average age was 46 years. Group 1 had higher pre-index
PPPM resource utilization for all categories than the 2 control
groups. However, compared with pre-index utilization, all post-
index resource utilization categories, except emergency room
visits, showed a signiﬁcant decrease for Group 1 that was not
consistently observed for controls. Inpatient admissions were
reduced in Group 1 (-16.28%), versus no change in Group 2,
and +4.17% for Group 3. Physician visits were reduced in Group
1 (–5.11%) versus +2.73% in Group 2, and +6.24% for Group
3. Non-anti-TNF prescriptions were reduced in Group 1
(-6.70%) versus +6.75% in Group 2, and +8.02% for Group 3.
CONCLUSION: Anti-TNF therapy appears to be associated
with a decrease in health care resource utilization. Additional
analyses to determine the effectiveness of anti-TNF therapies in
patients with IMIDs through clinical, economic, and humanistic
assessments are recommended.
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ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS
ATREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS
INTHE NETHERLANDS
Pompen M1, Diamantopoulos A2, Kievit W3, Moers R4, Kielhorn A5
1Roche Netherland BV,Woerden,The Netherlands, 2IMS Health,
London, UK, 3Radboud University Nijmegen Medical Centre,
Nijmegen,The Netherlands, 4Roche Nederland BV,Woerden,The
Netherlands, 5F. Hoffmann-La Roche AG, Basel, Switzerland
OBJECTIVES: A pharmacoeconomic analysis was performed to
determine the cost implications of providing rituximab (RTX, a
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